Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.32 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.32 |
| ▸ | PARP1 | P09874 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6226053 | 0.77 | MAPT (0.41) | CRBNPOLBGAAMEN1KMT2A | |
| SCHEMBL10242630 | 0.77 | MAPT (0.41) | CRBNPOLBGAAMEN1KMT2A | |
| SCHEMBL6226055 | 0.77 | MAPT (0.41) | CRBNPOLBGAAMEN1KMT2A | |
| SCHEMBL7588464 | 0.75 | — | — | |
| SCHEMBL13065453 | 0.75 | — | — | |
| SCHEMBL7588453 | 0.75 | — | — | |
| SCHEMBL28196413 | 0.74 | MEN1 (0.33) | POLBGAAMEN1KMT2AKDM4E | |
| SCHEMBL16221368 | 0.74 | MEN1 (0.33) | POLBGAAMEN1KMT2AKDM4E | |
| SCHEMBL27019949 | 0.73 | POLB (0.41) | CRBNPOLBGAAMEN1KMT2A | |
| SCHEMBL24569709 | 0.72 | CRBN (0.33) | CRBNPARP10PARP11PARP1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | CRBN 127/4885POLB 2487/4885GAA 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.